Get the Stockscreener App
51.92
1.05%
+0.54
Arcellx Inc stock is currently priced at $51.92, with a 24-hour trading volume of 337.07K.
It has seen a +1.05% increased in the last 24 hours and a -25.97% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $51.00 pivot point. If it approaches the $52.34 resistance level, significant changes may occur.
Previous Close:
$51.38
Open:
$51.35
24h Volume:
337.07K
Market Cap:
$2.77B
Revenue:
-
Net Income/Loss:
$-70.36M
P/E Ratio:
-13.11
EPS:
-3.96
Net Cash Flow:
$186.15M
1W Performance:
+0.52%
1M Performance:
-25.97%
6M Performance:
+62.61%
1Y Performance:
+16.70%
1D Range:
$50.87
$52.68
52W Range:
$30.74
$75.10
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
25 West Watkins Mill Road, Suite A, Gaithersburg
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
Zacks Investment Research
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Benzinga
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Benzinga
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
Benzinga
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
Zacks Investment Research
Arcellx Inc Stock (ACLX) Financials Data
Arcellx Inc (ACLX) Net Income 2024
ACLX net income (TTM) was -$70.36 million for the quarter ending December 31, 2023, a +62.71% increase year-over-year.
Arcellx Inc (ACLX) Cash Flow 2024
ACLX recorded a free cash flow (TTM) of $186.15 million for the quarter ending December 31, 2023, a +283.25% increase year-over-year.
Arcellx Inc (ACLX) Earnings per Share 2024
ACLX earnings per share (TTM) was -$1.47 for the quarter ending December 31, 2023, a +70.42% growth year-over-year.
About Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Its lead ddCAR product candidate is CART-ddBCMA, which is in Phase 1 clinical development for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The company is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
1.53%
3.38%
Cap:
|
Volume (24h):